al information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings.
1. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin
structures: when the infection is more than skin deep. Journal of
Antimicrobial Chemotherapy (2004) 53, Suppl. S2, ii37-ii50.
2. R. Finch (2006) Gram-positive infections: lessons learnt and novel
solutions Clinical Microbiology and Infection 12 (s8) , 3-8
3. Su Young Lee, Joseph L. Kuti, David P. Nicolau. Surgical Infections.
September 1, 2005, 6(3): 283-295. doi:10.1089/sur.2005.6.283.
4. Klevens RM, Korrison MA, et al. Invasive Methicillin-Resistant
Staphylococcus aureus Infections in the United States. JAMA, October
17, 2007-Vol 298, No. 15.
5. U.S. Food and Drug Administration. Battle of the Bugs: Fighting
Antibiotic Resistance. Accessed on May 28, 2008. Available at:
6. Scheinfeld N. Journal of Drugs in Dermatology. Jan 2007. A comparison
of available and investigational antibiotics for complicated skin
infections and treatment-resistant Staphylococcus aureus and
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Forest Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results2
. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD3
. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies4
. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression5
. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia6
. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)7
. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders8
. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers9
. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 110
. Romark Laboratories Raises $18 Million in Institutional Financing11
. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials